1.11

6.25% 0.07

Allarity Therapeutics Inc (ALLR)

Overview News Price History Financials Discussions Forecast Stock Split

Allarity Therapeutics Inc stock is traded at $1.11, with a volume of 1.86M. It is up +6.25% in the last 24 hours and up +9.41% over the past month. Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Previous Close:

$1.04

Open:

$1.11

24h Volume:

1.86M

Relative Volume:

1.17

Market Cap:

$4.61M

Revenue:

Net Income/Loss:

$-11.90M

P/E Ratio:

-0.00539

EPS:

-206.0125

Net Cash Flow:

$-12.75M

1W Performance:

-1.34%

1M Performance:

+9.41%

6M Performance:

+690.98%

1Y Performance:

-87.99%

1-Day Range:

$1.045

$1.12

1-Week Range:

$0.9701

$1.211

52-Week Range:

$0.1131

$9.196

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name

Allarity Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

401-426-4664

Address

24 SCHOOL ST., 2ND FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ALLR's Discussions on Twitter

Compare ALLR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLR Allarity Therapeutics Inc	1.11	4.61M	0	-11.90M	-12.75M	-206.01
VRTX Vertex Pharmaceuticals Inc	473.13	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	719.93	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	652.85	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	275.66	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.25	28.75B	3.30B	-501.07M	1.03B	-2.1146

Allarity Therapeutics Inc Stock (ALLR) Latest News

08:31 AM

Allarity Therapeutics Inc (NASDAQ: ALLR) Gain Of 13.46% Compared To 52-Week Low; YTD Fall -11.11% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel

08:31 AM

Feb 06, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect - Markets Insider

Feb 06, 2025

Allarity Therapeutics Announces Expansion of Phase 2 - GlobeNewswire

Feb 06, 2025

Allarity Therapeutics advances ovarian cancer drug trial - Investing.com

Feb 06, 2025

Breakthrough Ovarian Cancer Drug Shows 14-Month Durability: Allarity Advances Clinical Trial - StockTitan

Feb 06, 2025

Feb 05, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation - Markets Insider

Feb 05, 2025

Allarity Therapeutics Inc’s Shares Reel: -24.64% Quarterly Revenue Decline Amid 4.68M Market Cap - The InvestChronicle

Feb 05, 2025

Feb 03, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out - Markets Insider

Feb 03, 2025

ALLR’s earnings forecast for the current quarter - US Post News

Feb 03, 2025

Ratios Reveal: Breaking Down Allarity Therapeutics Inc (ALLR)’s Financial Health - The Dwinnex

Feb 03, 2025

Feb 01, 2025

Allarity Therapeutics Reaches Settlement in Principle with SEC - Defense World

Feb 01, 2025

Jan 31, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect - Markets Insider

Jan 31, 2025

Jan 30, 2025

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC - GlobeNewswire

Jan 30, 2025

Allarity's Stenoparib Shows 14-Month Patient Response as Company Nears SEC Resolution - StockTitan

Jan 30, 2025

Jan 29, 2025

2025-01-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect | NDAQ:ALLR | Press Release - Stockhouse Publishing

Jan 29, 2025

Jan 28, 2025

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jan 28, 2025

Jan 26, 2025

2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

Jan 26, 2025

Jan 25, 2025

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Jan 25, 2025

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire

Jan 25, 2025

Jan 20, 2025

No Stopping Allarity Therapeutics Inc (NASDAQ: ALLR)’s Stock Surged? - Stocks Register

Jan 20, 2025

Jan 19, 2025

2025-01-19 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

Jan 19, 2025

Jan 15, 2025

2025-01-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out | NDAQ:ALLR | Press Release - Stockhouse Publishing

Jan 15, 2025

Jan 09, 2025

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com

Jan 09, 2025